Tag: immune-cell engagers
-
ESMO Therapeutic Landscapes 2026: Understanding Toxicity in Multispecific Antibodies and Immune-Cell Engagers
Overview: Why toxicity matters in multispecific antibodies and immune-cell engagers The ESMO Therapeutic Landscapes webinar series returns in 2026 with a focused session on the toxicity profiles of next-generation biologics. Multispecific antibodies and immune-cell engagers represent a rapidly advancing frontier in cancer therapy, offering the promise of simultaneous targeting of tumor antigens and immune cells.…
-
ESMO Therapeutic Landscapes: Toxicity and Safety Management of Multispecific Antibodies and Immune-Cell Engagers
Overview of ESMO Therapeutic Landscapes 2026 The ESMO Therapeutic Landscapes webinar series returns in 2026 with a focused session on the toxicity and safety considerations surrounding multispecific antibodies and immune-cell engagers. Scheduled for February 18, 2026, this technical program brings together hematology-oncology clinicians, translational scientists, and pharmacovigilance experts to examine the real-world challenges of next-generation…
-
ESMO Therapeutic Landscapes: Toxicity of Multispecific Antibodies and Immune-Cell Engagers
Overview ESMO Therapeutic Landscapes 2026 is set to explore the safety profiles and clinical management of next-generation biologics, with a focused session on the toxicity of multispecific antibodies and immune-cell engagers. Scheduled for February 18, 2026, this technical webinar brings together leading oncologists, immunologists, and translational researchers to dissect risk factors, mechanism-based toxicities, and practical…